{
    "clinical_study": {
        "@rank": "107596", 
        "arm_group": [
            {
                "arm_group_label": "Dapoxetine", 
                "arm_group_type": "Experimental", 
                "description": "Dapoxetine is administered"
            }, 
            {
                "arm_group_label": "Udenafil", 
                "arm_group_type": "Experimental", 
                "description": "Udenafil is administered"
            }, 
            {
                "arm_group_label": "Udenafil and Dapoxetine", 
                "arm_group_type": "Experimental", 
                "description": "Udenafil and Dapoxetine are co-administered"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to investigate the pharmacokinetic drug interaction between Udenafil\n      and Dapoxetine in healthy male subjects\n\n      Design : Randomized, open-label, 3-treatment, 6-sequence, 3-period crossover study\n\n      Investigational Product : Udenafil, Dapoxetine"
        }, 
        "brief_title": "Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Male Subjects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male volunteers in the age between 20 and 45 years old at screening\n\n          -  Body mass index(BMI) in the range of 19 to 27 \u338f/\u33a1\n\n          -  Sitting position blood pressure down to meet the criteria at the time of screening\n             (90mmHg\u2264Systolic blood pressure\u2264140mmHg)\n\n        Exclusion Criteria:\n\n          -  History of clinically significant disease or kidney, liver and biliary system,\n             digestive system, respiratory, musculoskeletal, endocrine, neurological psychiatric\n             blood and tumor system, cardiovascular system, etc.\n\n          -  History of gastrointestinal diseases or gastrointestinal operation which might affect\n             the study drug absorption\n\n          -  Clinically significant hypersensitivity or with a history of hypersensitivity\n             reactions to Udenafil, Dapoxetine ingredients that included elements of the same\n             family of drugs, or other medications\n\n          -  \u2265 1.5 fold of normal upper limit(UNL) in the level of ALT, AST\n\n          -  Alcohol, excessive intake (>21 units/week)\n\n          -  Excessive smoker (>10 cigarette/day)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928563", 
            "org_study_id": "DA8159_DIP_I"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dapoxetine", 
                "intervention_name": "Dapoxetine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Brand name : Priligy", 
                    "Dapoxetine is administered"
                ]
            }, 
            {
                "arm_group_label": "Udenafil", 
                "intervention_name": "Udenafil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Brand name : Zydena", 
                    "Code name : DA-8159", 
                    "Udenafil is administered"
                ]
            }, 
            {
                "arm_group_label": "Udenafil and Dapoxetine", 
                "intervention_name": "Udenafil+Dapoxetine", 
                "intervention_type": "Drug", 
                "other_name": "Udenafil and Dapoxetine are co-adminstered"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Udenafil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 21, 2013", 
        "location": {
            "contact": {
                "email": "ksbae@amc.seoul.kr", 
                "last_name": "Kyun-Seop Bae, M.D., Ph.D.", 
                "phone": "+82-2-3010-4611"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Songpa-gu", 
                    "zip": "138-786"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Kyun-Seop Bae, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine in Healthy Male Subjects", 
        "overall_contact": {
            "email": "byg@donga.co.kr", 
            "last_name": "Yong-Goo Bae, MSc", 
            "phone": "+82-2-920-8521"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Kyun-Seop Bae, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Cmax and AUClast of Udenafil and Dapoxetine", 
            "safety_issue": "No", 
            "time_frame": "Blood gathering point : 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, 48h (each period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928563"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC0-00, Tmax, T1/2\u03b2 of Udenafil and Dapoxetine AUClast, Cmax, Tmax, t1/2\u03b2 of DA-8164(major metabolite of Udenafil) and Desmethyl dapoxetine(major metabolite of Dapoxetine)", 
            "safety_issue": "No", 
            "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, 48h (each period)"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Dong-A ST Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}